Share Name Share Symbol Market Type Share ISIN Share Description
Kromek LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.125p +7.59% 30.125p 29.75p 30.50p 30.375p 28.75p 28.75p 2,496,708 14:05:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.3 -4.1 -1.5 - 78.03

Kromek (KMK) Latest News (3)

More Kromek News
Kromek Takeover Rumours

Kromek (KMK) Share Charts

1 Year Kromek Chart

1 Year Kromek Chart

1 Month Kromek Chart

1 Month Kromek Chart

Intraday Kromek Chart

Intraday Kromek Chart

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
30/4/201716:02Kromek Group PLC1,157.00
19/5/201508:23Kromek Group (KMK) - Overvalued AIM mugging177.00

Add a New Thread

Kromek (KMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

Kromek Daily Update: Kromek is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 28p.
Kromek has a 4 week average price of 26.50p and a 12 week average price of 20.50p.
The 1 year high share price is 34.50p while the 1 year low share price is currently 18.50p.
There are currently 259,015,618 shares in issue and the average daily traded volume is 363,347 shares. The market capitalisation of Kromek is £78,028,454.92.
bapodra_investments: I thought exactly the same that the market cap was way to high. However, with stocks like Kromek who have an edge and there is not as much competition and their products have USP's then it is not entirely unreasonable to see market caps such as with Kromek. It is based on high growth and huge potential. I accept that if Kromek does not deliver the necessary growth in turnover then the market cap would adjust based on falling share price as a result. Whilst the market thinks Kromek can deliver then the market cap will only increase as the share price increases. There could be some huge announcements by Kromek and there is a nice upward trend at present so would not want to miss out and be out of the share at this moment in time. Momentum is building.
bapodra_investments: I think once market sentiment gets behind Kromek then this should help increase volume and share price. The current political tensions around the world involving the US, Russia and North Korea can only help to enhance the credibility and enhance the need for some of Kromek's product offerings. They have raised £20m and have plenty of firepower and cash on the balance sheet. I am expecting some significant contract win RNS's from now till December 2017 and potential investors will rue the chance of not investing in today's prices. This is one of those rare Nano Cap shares that one can see in years to come being listed on the FTSE 350. It also has massive takeover potential. It is earning revenue unlike the majority of AIM shares. Imagine the share price if Kromek ever became profitable?
hyperboreus: Not wishing to comment on anything that has gone before but ST did in fact reply yesterday to patient_investor regarding Kromek in his comments section basically just reiterating his current stance on the Company: 1:17 PM on 11/4/2017 Hi Simon, Please could you provide your thoughts on KMK share price returning to 26.40p, a fall of some 30% since their inevitable spike in the aftermath of your tip? Do you still rate the shares a "strong buy"? Regards Patient SIMONTHOMPSON 1:36 PM on 11/4/2017 Patient I advised buying Kromek shares at 25p on Monday, 27 February after which almost 12 million shares traded in 689 bargains in the following two days. The weight of money continued to chase the shares and this meant that the share price moved up 36 per cent from 25.5p on the offer at 12pm on Monday 27 February to a high of 34.9p on Tuesday 7 March. In my analysis I stated that: "From my lens, the bottom is now in place and a break-out above the 25p resistance is highly likely, suggesting a sharp move to the 30p resistance level that halted progress last summer. Beyond that analyst's 34p a share price targets come firmly into play." I can't blame anyone for taking a 36 per cent profit in the space of a week. I would also mention that the Daily Telegraph subsequently tipped the shares which accentuated the rise and a fair amount of that buying was hot money, hence the subsequent fall. Nothing has changed in terms of the investment case as I still believe that 34p a share is fair value. I would flag up that subsequent to my article, on 24 March 2017, Berry Beumer, Chief Operating Officer of Kromek, purchased 80,000 Ordinary Shares at a price of 29.35 pence per share. Also, Kromek has also been awarded a contract, valued at $990k, by an existing US-based customer, a global leader in aerospace and defence technologies, for the upgrade of the Company's advanced security screening detectors that the customer has deployed since 2009. I believe the shares rate a buy at 26p. I hope this clarifies matters. Best wishes
quepassa: PS. Trotters - a little unnecessary perhaps to call me stubborn. And by the way, isn't that rather the kettle calling the pot black? This is an extract from your post no. 545 dated 29/4/16 when the share price was near 40p "look back at the trading activity here over the past few days and will see the majority of the larger trades are buys. That tells me the smart money (likely II's) are accumulating. When the next DARPA deal is announced in the coming months you will not be able to buy this share sub 50p As it will be heavily marked up from the open." Well, the cold light of reality has proved to be very different indeed to what you have been saying. Faced with this reality, who actually is the stubborn one? The share is a whopping 50% down from the date of your post and 60% down on your 50p forecast. It is clear that your calls have been very wide of the mark. Whilst I may be bearish, perhaps that stance has proved a lot more accurate than your hitherto stubbornly repetitive assertions about the skywards share price evolution of KMK. ALL IMO. DYOR. QP
quepassa: The company marketed the original flotation on figures and forecasts which approx six months later caused a shock RNS to be released about missed sales forecasts that in turn collapsed the share price. Kromek then issued on 4/4/14 an RNS about a $159m contract detailing dates and precise expected yearly revenues from that contract. Has the 4/4/14 RNS been reliable and held water? How much of his own money has the CEO put into the new equity highly dilutive issue? As in the past, a blue-skies scenario again seems to be being painted about Kromek's prospects. In the past those blue-skies have in my opinion rather turned out to be more like storm-force headwinds and gales with the share price still some 60% below flotation price and with several trips to the equity trough to keep the aspidistra flying. In my opinion only, I think this share is an absolute dog and I personally would not now touch it even with a very, very, very long barge pole. Good Luck All But perhaps keep on counting your fingers. Frequently. ALL IMO. DYOR. QP
ali47fish: nobody know where the share price will be - it does not give an advantage to pay over the current share price- im not sure i can follow the resoning abovetools please explain more- thanks
2niffy: Company is burning through cash. Any significant order would require an increase in working cap, mobilisation costs etc which are not factored into brokers forecasts. Customer unlikely to place order without surety of companies financial strength. Refinancing required. Could be done in various ways but probably via institutional placing with private clients getting diluted out of sight. Their last fundraising at 25p a circ 30% discount to the then prevailing share price. Miton in strong position to dictate terms re financing and a lower share price strengthens their hand.
quepassa: yes, very convincing......"Tumps focus on homland" let's be realistic, their sales are pretty microscopic and management do not convince in my opinion. Kromek have been back to the equity trough once or twice already and they have tested the faith of investors by issuing a shock warning on sales just a few months after flotation and now won't even give chapter and verse on their 4/4/14 RNS announcement about the mega $159million contract. Where are the sales for the airport scanners, the medical imaging equipment which were so much spoken of? We hear repeatedly about a series of smallish contracts from Darpa for some cheap-to-buy handheld devices but what about the big ticket medical imaging equipment and the high-spec security scanning equipment. What about sales for that? I personally can understand the share price slipping and the market becoming disenchanted. There is a big gulf in my opinion between the talk and the walk at Kromek. Don't blame Amphion for share price weakness because if Kromek were so attractive, some institution would have bitten Amphion's arm off to acquire their full position. Good luck all but carefully weigh reality against over zealous expectations. ALL IMO. DYOR. QP
culford: Bapodra, Valuation of loss making companies is difficult. You suggest £20m maximum and I would be interested in why? Is that a suitable discount to the net assets of £24m? Or is it 2.5x historic sales? The market is always right on any day and my interest is whether its worth buying or selling on a longer term view. My thought process is as follows. With KMK, there is enough evidence to show that sales will grow substantially, probably to >$100m per annum in due course. A company trades at a multiple of sales according to its margin and growth rate. A mature company with 10% margin will trade at c1x sales. KMK is fast growing and has high margins and I believe should trade on c5x sales - this would be 5x £9m this year and 5x £12m next year taking the consensus forecasts. That would be market cap of £45m rising to £60m or 29p share price rising to 38p. At any stage in this next 18 months it could get an order worth >£12m per annum, which would at least double that 38p to 76p. Thus in my view, buying KMK is at a 45% discount to next year's fundamental value on basis of no big contracts coming in. If and when they come in, I will at least triple my money.
culford: QP KMK has disappointed the markets and its share price is languishing accordingly. In year to April 13 its revenues were £2.7m and in year to April 16 its revenues were £8.3m - a growth of threefold over three years. In the last year, when it attracted Sir Peter Williams to become its Chairman, its orders received were $30m, or c£24m, but these will be received over multiple years. In the current year, sales will be marginally higher at c£9m. In the past year it has become sole supplier to Darpa, the US agency to which it has supplied >$6m of sales. Darpa has said that it will increase the size of its nuclear detection tests (which need KMK's devices) in 2017 before rolling this out to c15 US cities in 2018. See last news: KMK will receive orders of c$10m for each city so that is orders of c$150m to be received from end of 2017 for 2018 and beyond. In October it received orders for a military solution for the US and UK military, which will be of similar scale and slightly later timing. Thus whilst i share your disappointment on the share performance, you cannot say that there is a diminutive growth in sales and the potential growth can be checked from third party sources.
Kromek share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170430 16:39:44